Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36565199/
Background Outcomes and treatment effects of therapy may vary according to the cause of heart failure (HF). Methods and Results In this post hoc analysis of the EMPEROR-Reduced (Empagliflozin Outcome...
Conclusions: Empagliflozin offers cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of the cause of HF.
Share
Constantly Bombarded with New Drugs: What's a Cardiologist to Do?
Source : https://journal.houstonmethodist.org/articles/10.14797/mdcvj.1179
Every physician encounters a barrage of direct-to-consumer and direct-to-physician advertising and is faced with the daunting task of deciding which drugs to add to their clinical armamentarium and how and...
Conclusions: This article focuses on a single drug, empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has been highly marketed in lay and medical media and hence has been incorporated into professional society treatment guidelines.
Share
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36548322/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: While evidence of CV benefits grows, SGLT2 inhibitor prescribing has lagged, particularly among patients without diabetes. In the U.S., high cost and administrative hurdles may contribute to decreased patient and clinician uptake of this drug class. Future trial results and clinical experience with SGLT2 inhibitors may lead to...
Share
Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial
Source : https://www.sciencedirect.com/science/article/abs/pii/S0002870322003258?via=ihub
Available online 8 December 2022 Author links open overlay panel Yu Horiuchi 1 2 # Yuya Matsue 2 Person # Envelope Show more The aim of the EMPA-AHF trial is...
Conclusion: The EMPA-AHF trial is the first to evaluate the efficacy and safety of early initiation of empagliflozin in patients with AHF considered to be at high risk under conventional treatment.
Share
Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction
Source : https://www.sciencedirect.com/science/article/pii/S2352906722002111?via=ihub
Despite the obesity paradox, visceral adiposity is associated with poor clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unclear whether a relationship between...
Conclusions: In lean East Asian patients with HFpEF, a lower VAT volume was associated with poorer clinical outcomes. CT-based assessments of adiposity may provide incremental prognostic value over simple anthropometric indices in lean HFpEF patients.
Share